leukemia

[Blood] Researchers showed that transcriptional downregulation of PU.1 was an active process involving an alternative promoter in intron 3 that was induced by RUNX transcription factors driving noncoding antisense transcription.

[Blood Advances] Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.

[Blood Advances] 43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.

[LAVA Therapeutics N.V.] LAVA Therapeutics N.V. announced that the US FDA has granted orphan drug designation for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.

[BMC Cancer] Investigators conducted microarray gene expression analysis and compared FX-9 exposed and unexposed prostate cancer cells, followed by pathway analysis and gene annotation to functional processes.

[Oncology and Therapy] Researchers hypothesized that progressive changes in gene expression resulted in malignant transformation of B lymphocytes to family histroy of monoclonal B lymphocytosis, and subsequent alterations in gene expression occur before overt family history of chronic lymphocytic leukemia develops.